



Date: 28th October, 2022

To,
BSE Limited
P. J. Towers, Dalal Street, Fort
Mumbai – 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai-400 051

Ref.: BSE Scrip Code No. "533138"

Ref.: "ASTEC"

Sub.: Outcome of the Board Meeting

Pursuant to Regulations 30, 33 and 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Schedule III to the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e., on **Friday, 28th October, 2022** (which commenced at 3.30 p.m. and concluded at 4.25 p.m.), *inter alia*, has approved / noted the following:

(a) APPROVAL OF THE UNAUDITED FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED) FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2022:

Upon recommendation of the Audit Committee, the Board of Directors has approved the Unaudited Financial Results (Standalone & Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter and Half Year ended 30th September, 2022 along with Cash Flow Statement and the Statement of Assets and Liabilities as on 30th September, 2022 (enclosed herewith).

(b) NOTING OF THE STATUTORY AUDITORS' LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL RESULTS (STANDALONE & CONSOLIDATED) FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2022:

The Board of Directors took note of the Limited Review Report of the Statutory Auditors on the Unaudited Financial Results (Standalone & Consolidated) for the Quarter and Half Year ended 30th September, 2022 (enclosed herewith).

The Limited Review Report of the Statutory Auditors is with unmodified opinion with respect to the Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Half Year ended 30th September, 2022.

(c) APPOINTMENT OF MR. MADHUR GUNDECHA AS THE "CHIEF FINANCIAL OFFICER" OF THE COMPANY:

The Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee, has appointed Mr. Madhur Gundecha as the "Chief Financial Officer" of the Company with effect from 28th October, 2022.

Disclosure required pursuant to Regulation 30 of the Listing Regulations, read with Para A of Part A of Schedule III to the Listing Regulations, with regard to change in Directors and Key Managerial Personnel is given hereunder:





ASTEC

Astec LifeSciences Ltd.

Sr. No.	Disclosure Requirement	Details
1.	Reason for Change, viz. appointment, resignation, removal, death or otherwise	The Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee, has appointed Mr. Madhur Gundecha as the "Chief Financial Officer" of the Company with effect from 28 th October, 2022.
2.	Date of Appointment / Cessation (as applicable) & term of Appointment	Appointment with effect from 28 th October, 2022.
3.	Brief Profile	Mr. Madhur Gundecha has over 23 years' experience working in leading companies such as Omniactive Health Technologies, Johnson Matthey Chemicals, BASF, Godrej Agrovet Limited & Bharat Petroleum Corporation Limited. He has a proven track record of spearheading Finance function and generating value by establishing financial policies, procedures, controls and reporting systems. He has held various leadership positions with responsibilities for Controllership, FP&A, Operational Finance and Treasury. He is a qualified Chartered Accountant and Cost Accountant. He is also a CFA Level 3 candidate.
4.	Disclosure of Relationships between Directors (in case of Appointment of a Director)	Not Applicable

Please take the above information on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)

Encl.: As above



Regd. Office :
"Godrej One", 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai-400079,
Maharashtra, India
Telephone No.: 022- 25188010
Fax No.: 022-22618289
Email id: astecinfo@godrejastec.com
Website: www.astecsl.com
CIN : L99999MH1994PLC076236



Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year ended 30th September, 2022



(Rs. in Lakh)

Sr. No	Particulars	STANDALONE					
		Quarter Ended			Year to date figures for the period ended		Year ended
		30-Sep-22	30-Jun-22	30-Sep-21	30-Sep-22	30-Sep-21	31-Mar-22
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operations	19,974.70	18,426.63	10,257.44	38,401.33	23,123.09	67,656.61
II	Other Income	398.21	270.67	89.93	668.88	170.32	1,046.34
III	Total Income (I+II)	20,372.91	18,697.30	10,347.37	39,070.21	23,293.41	68,702.95
IV	Expenses						
	Cost of materials consumed	13,468.35	13,863.65	9,163.03	27,332.00	17,797.61	44,481.50
	Changes in inventories of finished goods and work-in-progress	(1,188.70)	(1,615.51)	(4,031.90)	(2,804.21)	(4,826.00)	(5,800.42)
	Employee benefits expense	1,502.74	1,297.78	1,146.69	2,800.52	2,073.78	5,031.41
	Finance costs	452.10	393.03	165.89	845.13	319.66	909.02
	Depreciation and amortisation expense	818.41	894.23	816.68	1,712.64	1,468.86	3,441.59
	Other expenses.	2,864.15	2,335.43	1,871.13	5,199.58	3,501.97	8,535.77
	Total expenses (IV)	17,917.05	17,168.61	9,131.52	35,085.66	20,335.88	56,598.87
V	Profit / (loss) before exceptional items and tax (III - IV)	2,455.86	1,528.69	1,215.85	3,984.55	2,957.53	12,104.08
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit / (loss) before tax (V-VI)	2,455.86	1,528.69	1,215.85	3,984.55	2,957.53	12,104.08
VIII	Tax Expense:						
	(1) Current tax	162.59	98.63	273.97	261.22	708.55	2,861.27
	(2) Deferred tax	463.47	291.08	35.57	754.55	45.18	261.01
IX	Profit / (loss) for the period from continuing operations (VII - VIII)	1,829.80	1,138.98	906.31	2,968.78	2,203.80	8,981.80
X	Profit / (loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-	-	-
XII	Profit / (loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit / (loss) for the period (IX + XII)	1,829.80	1,138.98	906.31	2,968.78	2,203.80	8,981.80
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	(0.50)	(0.50)	(5.88)	(1.00)	(11.77)	(0.72)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.12	0.13	1.48	0.25	2.96	0.18
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period)	1,829.42	1,138.61	901.91	2,968.03	2,194.99	8,981.26
XVI	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,960.46	1,959.76	1,958.91	1,960.46	1,958.91	1,959.76
XVII	Other Equity excluding Revaluation Reserve						37,638.34
XVIII	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinuing operations) (non-annualised) :						
	(1) Basic (in Rs.)	9.34	5.81	4.63	15.15	11.25	45.85
	(2) Diluted (in Rs.)	9.33	5.81	4.62	15.14	11.24	45.83

Notes:

- The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Friday, 28th October, 2022.
- The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to limited review by the Statutory Auditors of the Company and they have expressed an unmodified review opinion.
- The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards employment and post-employment benefits. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its valuation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which the Code becomes effective.
- The figures for the previous year/periods have been re-grouped/re-classified wherever necessary, to conform to current period's presentation.

For Astec LifeSciences Limited

Anurag Roy

Anurag Roy
 Whole – Time Director & Chief Executive Officer
 DIN : 07444595
 Place : Mumbai
 Date : October 28 , 2022



BURJIS
TEHMURASP
PARDIWALA

Digitally signed by
 BURJIS
 TEHMURASP
 PARDIWALA
 Date: 2022.10.28
 15:52:48 +05'30'

**Astec LifeSciences Limited**

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com



Additional disclosures as per Clause 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No	Particulars	STANDALONE					
		Quarter Ended			Year to date figures for the period ended		Year ended
		30-Sep-22	30-Jun-22	30-Sep-21	30-Sep-22	30-Sep-21	31-Mar-22
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Current Ratio (refer note 1)	1.13	1.08	0.88	1.13	0.88	1.05
II	Net Worth (in Rs. Lakh)	42,303.73	40,755.93	32,777.43	42,303.73	32,777.43	39,598.10
III	Capital Redemption Reserve (in Rs. Lakh)	0.30	0.30	0.30	0.30	0.30	0.30
IV	Debt Equity ratio (refer note 1)	0.76	0.87	0.57	0.76	0.57	0.71
V	Debt Service Coverage Ratio (DSCR) (refer note 1)	6.56	5.28	9.83	5.93	10.67	13.10
VI	Interest Service Coverage Ratio (ISCR) (refer note 1)	6.97	6.19	11.44	6.60	12.49	14.67
VII	Long term debt to working capital (refer note 1)	0.49	0.26	-	0.49	-	-
VIII	Bad debts to Account receivable ratio (refer note 1)	-	-	-	-	-	-
IX	Current liability ratio (refer note 1)	0.91	0.96	0.98	0.91	0.98	0.98
X	Total debts to total assets (refer note 1)	0.34	0.36	0.26	0.34	0.26	0.31
XI	Debtors turnover (refer note 1)	2.88	2.70	2.69	2.92	2.94	2.92
XII	Inventory turnover (refer note 1)	4.00	3.86	2.94	3.93	3.37	4.62
XIII	Operating EBITDA margin (%)	16.66%	13.81%	20.56%	15.29%	19.79%	22.77%
XIV	Net profit margin (%)	9.16%	6.18%	8.84%	7.73%	9.53%	13.28%

1 Pursuant to SEBI Operational Circular for Issue and Listing of Non-Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated 10th August, 2021, the Company has listed Commercial Papers on National Stock Exchange (NSE).

The Company is rated by leading credit agency ICRA. The rating "[ICRA] A1+" and "[ICRA] AA-" has been assigned for its short term facilities (including commercial paper) and long term facilities respectively.

Formulac for computation of ratios:

Current ratio : Current assets / Current liabilities

Debt Equity ratio : Total Debt / Shareholder's Equity

Debt Service Coverage Ratio : (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / (Interest & Lease Payments + Principal Repayments)

Interest service coverage ratio: (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / Interest expense

Long term debt to working capital : Non-current borrowings / (Current Assets - Current liabilities)

Bad debts to Account receivable ratio : Bad debts including provision for doubtful debts / Average Trade receivable.

Current liability ratio : Current liabilities / Total liabilities

Total debts to total assets : Total borrowings / Total assets

Debtors turnover : Net Credit Sales / Average Trade Receivable (annualised)

Inventory turnover : Total Sales / Average Inventory (annualised).

AR



BURJIS
TEHMURASP
PARDIWALA
Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2022.10.28
15:53:11 +05'30'

**Astec LifeSciences Limited**

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.: 022-2519 5768. Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Half Year ended 30th September, 2022



(Rs. in Lakh)

Sr. No	Particulars	CONSOLIDATED					
		Quarter Ended			Year to date figures for the period ended		Year ended
		30-Sep-22 (Unaudited)	30-Jun-22 (Unaudited)	30-Sep-21 (Unaudited)	30-Sep-22 (Unaudited)	30-Sep-21 (Unaudited)	31-Mar-22 (Audited)
I	Revenue from Operations	19,974.70	18,426.63	10,257.44	38,401.33	23,123.09	67,656.61
II	Other Income	398.59	271.04	89.93	669.63	170.32	1,046.78
III	Total Income (I+II)	20,373.29	18,697.67	10,347.37	39,070.96	23,293.41	68,703.39
IV	Expenses						
	Cost of materials consumed	13,468.35	13,863.65	9,163.03	27,332.00	17,797.61	44,481.50
	Changes in inventories of finished goods and work-in-progress	(1,188.70)	(1,615.51)	(4,031.90)	(2,804.21)	(4,826.00)	(5,800.42)
	Employee benefits expense	1,502.74	1,297.78	1,146.69	2,800.52	2,073.78	5,031.41
	Finance costs	451.45	392.39	165.07	843.84	318.03	905.77
	Depreciation and amortisation expense	816.92	892.74	815.19	1,709.66	1,465.88	3,435.63
	Other expenses.	2,864.43	2,335.69	1,871.37	5,200.12	3,502.56	8,536.92
	Total expenses (IV)	17,915.19	17,166.74	9,129.45	35,081.93	20,331.86	56,590.81
V	Profit / (loss) before exceptional items and tax (III - IV)	2,458.10	1,530.93	1,217.92	3,989.03	2,961.55	12,112.58
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit / (loss) before tax (V-VI)	2,458.10	1,530.93	1,217.92	3,989.03	2,961.55	12,112.58
VIII	Tax Expense:						
	(1) Current tax	163.20	99.24	274.53	262.44	709.56	2,863.40
	(2) Deferred tax	463.42	291.03	35.61	754.45	45.13	260.92
IX	Profit / (loss) for the period from continuing operations (VII-VIII)	1,831.48	1,140.66	907.78	2,972.14	2,206.86	8,988.26
X	Profit / (loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-	-	-
XII	Profit / (loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit / (loss) for the period (IX + XII)	1,831.48	1,140.66	907.78	2,972.14	2,206.86	8,988.26
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	(0.50)	(0.50)	(5.88)	(1.00)	(11.77)	(0.72)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.12	0.13	1.48	0.25	2.96	0.18
	B (i) Items that will be reclassified to profit or loss	0.42	0.46	0.15	0.88	0.14	(0.18)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period)	1,831.52	1,140.75	903.53	2,972.27	2,198.19	8,987.54
XVI	Net Profit/(loss) attributable to:						
	- Owners	1,830.82	1,139.99	907.24	2,970.81	2,205.72	8,985.86
	- Non controlling interests	0.66	0.67	0.54	1.33	1.14	2.40
	Total Comprehensive Income attributable to:						
	- Owners	1,830.86	1,140.08	902.99	2,970.94	2,197.05	8,985.14
	- Non controlling interests	0.66	0.67	0.54	1.33	1.14	2.40
XVII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,960.46	1,959.76	1,958.91	1,960.46	1,958.91	1,959.76
XVIII	Other Equity excluding Revaluation Reserve	-	-	-	-	-	37,689.78
XIX	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinuing operations) (non-annualised) :						
	(1) Basic (in Rs.)	9.34	5.82	4.63	15.16	11.26	45.87
	(2) Diluted (in Rs.)	9.34	5.81	4.63	15.15	11.25	45.85

Notes:

- The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Friday, 28th October, 2022.
- The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to limited review by the Statutory Auditors of the Company and they have expressed an unmodified review opinion.
- The Group has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards employment and post-employment benefits. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its valuation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which the Code becomes effective.
- The figures for the previous year/periods have been re-grouped/re-classified wherever necessary, to conform to current period's presentation.

For Astec LifeSciences Limited

Anurag Roy



BURJIS
TEHMURAS
P
PARDIWALA

Digitally signed by
BURJIS
TEHMURAS
PARDIWALA
Date: 2022.10.28
15:53:30 +05'30'

Whole – Time Director & Chief Executive Officer

DIN : 07444595

Place : Mumbai

Date : October 28 , 2022



Additional disclosures as per Clause 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No	Particulars	CONSOLIDATED					
		Quarter Ended			Year to date figures for the period ended		Year ended
		30-Sep-22 (Unaudited)	30-Jun-22 (Unaudited)	30-Sep-21 (Unaudited)	30-Sep-22 (Unaudited)	30-Sep-21 (Unaudited)	31-Mar-22 (Audited)
I	Current Ratio (refer note 1)	1.13	1.08	0.88	1.13	0.88	1.05
II	Net Worth (in Rs. Lakh)	42,358.07	40,808.83	32,827.04	42,358.07	32,827.04	39,649.54
III	Capital Redemption Reserve (in Rs. Lakh)	0.30	0.30	0.30	0.30	0.30	0.30
IV	Debt Equity ratio (refer note 1)	0.76	0.87	0.57	0.76	0.57	0.70
V	Debt Service Coverage Ratio (DSCR) (refer note 1)	6.59	5.31	9.90	5.96	10.81	13.23
VI	Interest Service Coverage Ratio (ISCR) (refer note 1)	6.97	6.20	11.44	6.61	12.55	14.72
VII	Long term debt to working capital (refer note 1)	0.49	0.25	-	0.49	-	-
VIII	Bad debts to Account receivable ratio (refer note 1)	-	-	-	-	-	-
IX	Current liability ratio (refer note 1)	0.91	0.96	0.98	0.91	0.98	0.98
X	Total debts to total assets (refer note 1)	0.34	0.36	0.26	0.34	0.26	0.31
XI	Debtors turnover (refer note 1)	2.88	2.70	2.69	2.92	2.94	2.92
XII	Inventory turnover (refer note 1)	4.00	3.86	2.94	3.93	3.37	4.62
XIII	Operating EBITDA margin (%)	16.66%	13.81%	20.55%	15.29%	19.79%	22.77%
XIV	Net profit margin (%)	9.17%	6.19%	8.85%	7.74%	9.54%	13.29%

I Pursuant to SEBI Operational Circular for Issue and Listing of Non-Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated 10th August, 2021, the Company has listed Commercial Papers on National Stock Exchange (NSE).

The Company is rated by leading credit agency ICRA. The rating "[ICRA] A1+" and "[ICRA] AA-" has been assigned for its short term facilities (including commercial paper) and long term facilities respectively.

Formulae for computation of ratios:

Current ratio : Current assets / Current liabilities

Debt Equity ratio : Total Debt / Shareholder's Equity

Debt Service Coverage Ratio : (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / (Interest & Lease Payments + Principal Repayments)

Interest service coverage ratio: (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / Interest expense

Long term debt to working capital : Non-current borrowings / (Current Assets - Current liabilities)

Bad debts to Account receivable ratio : Bad debts including provision for doubtful debts / Average Trade receivable.

Current liability ratio : Current liabilities / Total liabilities

Total debts to total assets : Total borrowings / Total assets

Debtors turnover : Net Credit Sales / Average Trade Receivable (annualised)

Inventory turnover : Total Sales / Average Inventory (annualised).

ARoy



BURJIS
TEHMURASP
PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2022.10.28
15:53:44 +05'30'



Astec LifeSciences Limited
Corporate Identity Number : L99999MH1994PLC076236
Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra
Website: www.astecsl.com, Tel no.:022-25195768, Fax no.: 022-22618289, Email id: astecin@godrejastec.com
Statement of Cash Flows for the Half Year ended 30th September, 2022



(Rs. in Lakh)

PARTICULARS	STANDALONE		CONSOLIDATED	
	Period Ended		Period Ended	
	30-Sep-22 (Unaudited)	30-Sep-21 (Unaudited)	30-Sep-22 (Unaudited)	30-Sep-21 (Unaudited)
I Cash flow from operating activities				
Profit before tax	3,984.55	2,957.53	3,989.03	2,961.55
Adjustments for				
Depreciation and amortisation expense	1,712.64	1,468.86	1,709.66	1,465.88
Interest income	(140.82)	(18.79)	(141.57)	(18.79)
Finance cost paid	845.13	319.66	843.84	318.03
Unrealised foreign exchange (gain)/loss	26.82	(116.95)	26.82	(116.95)
Loss allowance - trade receivables	-	17.56	-	17.56
Loss allowance - other receivables	(7.11)	-	(7.11)	-
Loss/(Gain) on sale of property, plant and equipment	54.19	-	54.19	-
Employee stock options expense	18.68	-	18.68	-
	2,509.53	1,670.34	2,504.51	1,665.73
Operating Profit Before Working Capital Changes	6,494.08	4,627.87	6,493.54	4,627.28
Adjustments for				
(Increase)/Decrease in trade receivables	5,185.24	6,082.11	5,185.24	6,082.11
(Increase)/Decrease in loans	13.83	(3.48)	13.83	(3.48)
(Increase)/Decrease in other financial assets	200.14	116.72	200.14	116.72
(Increase)/Decrease in other current assets	660.99	(119.30)	661.28	(119.01)
(Increase)/Decrease in inventories	(1,681.51)	(6,227.66)	(1,681.51)	(6,227.66)
(Increase)/Decrease in other non-current assets	-	124.86	-	124.86
Increase/(Decrease) in trade payables	(815.90)	4,309.52	(819.98)	4,305.09
Increase/(Decrease) in other financial liabilities	(440.17)	(150.29)	(440.19)	(150.29)
Increase/(Decrease) in other current liabilities	(555.93)	3.22	(555.84)	3.51
Increase/(Decrease) in provisions	29.74	(17.38)	29.75	(17.39)
Increase/(Decrease) in other non-current financial liabilities	40.00	-	40.00	-
Cash generated from operations	9,130.51	8,746.19	9,126.26	8,741.74
Direct Taxes paid (net of refunds received)	(448.14)	(1,210.78)	(449.37)	(1,211.74)
Net cash flow generated from Operating activities	8,682.37	7,535.41	8,676.89	7,530.00
II Cash flow from investing activities				
Acquisition of property, plant and equipment and capital work-in-progress	(4,586.84)	(6,993.65)	(4,586.83)	(6,993.65)
Proceeds from sale of property, plant and equipment	15.30	-	15.30	-
Deposits redeemed / (placed)	(7,315.75)	(2.46)	(7,316.42)	(2.46)
Interest received	137.41	27.71	138.16	27.71
Net cash flow used in Investing activities	(11,749.88)	(6,968.40)	(11,749.79)	(6,968.40)
III Cash flow from financing activities				
Proceeds of Long term borrowings	(898.84)	-	(898.84)	-
Proceeds / (Repayment) of Short term borrowings (net)	5,076.21	24.10	5,076.21	24.10
Proceeds from issue of shares	12.98	5.96	12.98	5.96
Payment of lease liabilities	(5.39)	(5.41)	-	-
Finance cost paid	(859.57)	(298.50)	(859.58)	(298.50)
Dividend paid to company's shareholders	(294.07)	(293.78)	(294.07)	(293.78)
Net cash flow generated from / (used in) Financing activities	3,031.32	(567.63)	3,036.70	(562.22)
Net increase / (decrease) in cash and cash equivalents	(36.19)	(0.62)	(36.20)	(0.62)
Cash and cash equivalents as at the beginning of the year	54.46	32.94	55.45	33.88
Cash and cash equivalents as at the end of the period	18.27	32.32	19.25	33.26
Cash and Cash equivalents as per above comprises of the following				
Cash and Cash equivalents	18.27	32.32	19.25	33.26
Balance as per statement of Cash flow	18.27	32.32	19.25	33.26



BURJIS
TEHMURASP
PARDIWALA
Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2022.10.28
15:53:59 +05'30'



(Rs. in Lakh)

PARTICULARS	STANDALONE		CONSOLIDATED	
	As at 30th September, 2022	As at 31st March, 2022	As at 30th September, 2022	As at 31st March, 2022
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
ASSETS				
(1) Non-current assets				
(a) Property, Plant and Equipment	29,762.48	30,790.86	29,785.42	30,814.21
(b) Capital work-in-progress	2,711.89	1,373.24	2,711.89	1,373.24
(c) Right of use assets	3,035.63	2,967.49	3,021.97	2,950.45
(d) Other Intangible assets	189.73	229.79	189.73	229.79
(e) Intangible assets under development	1,160.17	909.25	1,160.17	909.25
(f) Investments in Subsidiaries	42.18	42.18	-	-
(g) Financial Assets				
(i) Investments	0.53	0.53	0.53	0.53
(ii) Other non-current financial assets	325.13	278.94	335.25	289.06
(h) Other Tax assets (net)	429.84	242.92	430.20	243.27
(i) Other non current assets	3,199.76	1,298.15	3,199.76	1,298.15
Total Non-current assets	40,857.34	38,133.35	40,834.92	38,107.95
(2) Current Assets				
(a) Inventories	20,376.15	18,694.64	20,376.15	18,694.64
(b) Financial Assets				
(i) Investments				
(ii) Trade Receivables	22,358.18	27,362.76	22,358.18	27,362.76
(iii) Cash and cash equivalents	18.27	54.46	19.25	55.45
(iv) Bank balances other than (iii) above	7,442.77	127.02	7,473.84	157.42
(v) Loans	0.79	14.62	0.79	14.62
(vi) Others	257.73	500.65	257.73	500.65
(c) Other current assets	4,129.60	4,783.48	4,128.01	4,782.18
Total Current Assets	54,583.49	51,537.63	54,613.95	51,567.72
Total Assets	95,440.83	89,670.98	95,448.87	89,675.67
EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	1,960.46	1,959.76	1,960.46	1,959.76
(b) Other Equity	40,343.27	37,638.34	40,397.61	37,689.78
(c) Non controlling interest	-	-	17.65	16.32
Total Equity	42,303.73	39,598.10	42,375.72	39,665.86
LIABILITIES				
(1) Non-current liabilities				
(a) Financial Liabilities				
(i) Borrowings	3,101.00	-	3,101.00	-
(ii) Lease liability	15.54	20.39	-	-
(iii) Other financial liabilities	140.00	100.00	140.00	100.00
(b) Provisions	42.77	42.77	42.77	42.77
(c) Deferred tax liabilities (net)	1,557.46	803.16	1,562.44	808.23
Total Non Current Liabilities	4,856.77	966.32	4,846.21	951.00
(2) Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	28,997.94	27,937.31	28,997.94	27,937.31
(ii) Lease liability	8.97	8.22	-	-
(iii) Trade payables				
Total outstanding dues of Micro, Small and Medium Enterprises	367.19	213.44	367.19	213.44
Total outstanding dues of creditors other than Micro, Small and Medium Enterprises	18,059.33	18,811.05	18,012.80	18,769.32
(iv) Other financial liabilities	651.26	1,415.71	652.84	1,417.48
(b) Other current liabilities	121.72	677.65	122.24	678.08
(c) Provisions	73.92	43.18	73.93	43.18
Total Current Liabilities	48,280.33	49,106.56	48,226.94	49,058.81
Total Equity and Liabilities	95,440.83	89,670.98	95,448.87	89,675.67


For Astec LifeSciences Limited

Anurag Roy
Whole – Time Director & Chief Executive Officer
DIN : 07444595
Place : Mumbai
Date : October 28 , 2022



BURJIS
TEHMURASP
PARDIWALA
Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2022.10.28
15:54:16 +05'30'

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East),
Mumbai - 400 063, India

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited Review Report on unaudited standalone financial results of Astec LifeSciences Limited for the quarter ended 30 September 2022 and year-to-date results for the period from 1 April 2022 to 30 September 2022 pursuant to Regulation 33 and Regulation 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021

To the Board of Directors of Astec LifeSciences Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Astec LifeSciences Limited ("the Company") for the quarter ended 30 September 2022 and year-to-date results for the period from 1 April 2022 to 30 September 2022 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Registered Office:

B S R & Co. LLP

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

BURJIS
TEHMURASP
PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2022.10.28
15:54:59 +05'30'

Burjis Pardiwala

Partner

Mumbai

28 October 2022

Membership No.: 103595

UDIN:22103595BBCRPR2511

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East),
Mumbai - 400 063, India

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited Review Report on unaudited consolidated financial results of Astec LifeSciences Limited for the quarter ended 30 September 2022 and year-to-date results for the period from 1 April 2022 to 30 September 2022 pursuant to Regulation 33 and Regulation 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021

To the Board of Directors of Astec LifeSciences Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Astec LifeSciences Limited ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 September 2022 and year-to-date results for the period from 1 April 2022 to 30 September 2022 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021.
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement:
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Registered Office:

B S R & Co. LLP

6. We did not review the financial information of One Subsidiary included in the Statement, whose financial information reflect total assets of Rs. 121.29 lakhs as at 30 September 2022 and total revenues of Rs. 3.08 lakhs and Rs. 6.15 lakhs, total net profit after tax of Rs. 1.93 lakhs and Rs. 3.86 lakhs and total comprehensive income of Rs. 1.93 lakhs and Rs. 3.86 lakhs, for the quarter ended 30 September 2022 and for the period from 1 April 2022 to 30 September 2022 respectively, and cash flows (net) of Rs Nil for the period from 1 April 2022 to 30 September 2022, as considered in the unaudited consolidated financial results. These interim financial information have been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

7. The Statement includes the financial information of One Subsidiary which have not been reviewed, whose financial information reflect total assets of Rs. 0.16 lakhs as at 30 September 2022 and total revenues of Rs. Nil and Rs. Nil, total net profit after tax of Rs. Nil and Rs. Nil and total comprehensive income Rs. Nil and Rs. Nil, for the quarter ended 30 September 2022 and for the period from 1 April 2022 to 30 September 2022 respectively, and cash flows (net) of Rs Nil for the period from 1 April 2022 to 30 September 2022, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

BURJIS
TEHMURASP
PARDIWALA
Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2022.10.28
15:55:24 +05'30'

Burjis Pardiwala

Partner

Mumbai

28 October 2022

Membership No.: 103595

UDIN:22103595BBCSRV2595

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Astec LifeSciences Limited	Holding Company
2	Behram Chemicals Private Limited	Comercializadora Agricola Agroastrachem Cia Ltda
3	Comercializadora Agricola Agroastrachem Cia Ltda	Comercializadora Agricola Agroastrachem Cia Ltda